# OnCo record paper-peace-1-lancet-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-peace-1-lancet-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-peace-1-lancet-2022" ;
  schema:name "Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design"@en ;
  schema:description "Published report from the PEACE-1 trial registered as NCT01957436, in The Lancet (2022), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-peace-1-lancet-2022/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s0140-6736(22)00367-1>, <https://pubmed.ncbi.nlm.nih.gov/35405085/>, <https://europepmc.org/article/MED/35405085>, <https://clinicaltrials.gov/study/NCT01957436> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s0140-6736(22)00367-1> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Fizazi K, Foulon S, Carles J, et al." ;
  onco:trials <https://onco.cc/trials/peace-1/> ;
  onco:journals <https://onco.cc/journals/lancet/> .